289 related articles for article (PubMed ID: 25106074)
1. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
Dolton MJ; McLachlan AJ
Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
3. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
6. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.
Veloso DFMC; Benedetti NIGM; Ávila RI; Bastos TSA; Silva TC; Silva MRR; Batista AC; Valadares MC; Lima EM
Drug Deliv; 2018 Nov; 25(1):1585-1594. PubMed ID: 30044149
[TBL] [Abstract][Full Text] [Related]
7. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
[TBL] [Abstract][Full Text] [Related]
8. Primary Cutaneous Aspergillosis in a Preterm Infant.
Frick MA; Boix H; Camba Longueira F; Martin-Gomez MT; Rodrigo-Pendás JÁ; Soler-Palacin P
Pediatr Infect Dis J; 2016 Jun; 35(6):704-6. PubMed ID: 26974892
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
11. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 is involved in the effect of Wuzhi tablet (
Yuan F; Liang X; Chen X; Qin X; Tan C; Wang L
Pharmazie; 2020 Nov; 75(11):559-564. PubMed ID: 33239129
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.
Elewa H; El-Mekaty E; El-Bardissy A; Ensom MH; Wilby KJ
Clin Pharmacokinet; 2015 Dec; 54(12):1223-35. PubMed ID: 26070947
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
16. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.
Gallego-Arranz T; Pérez-Cantero A; Torrado-Salmerón C; Guarnizo-Herrero V; Capilla J; Torrado-Durán S
Colloids Surf B Biointerfaces; 2020 Sep; 193():111119. PubMed ID: 32464356
[TBL] [Abstract][Full Text] [Related]
17. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
18. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
[TBL] [Abstract][Full Text] [Related]
19. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.
Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.
Amsden JR; Gubbins PO; McConnell S; Anaissie E
Antimicrob Agents Chemother; 2013 Jul; 57(7):3420-3. PubMed ID: 23629717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
